Clinical trial NCT06823271: Haemodynamics and Ventricular Arrhythmias During Exercise in Patients With Arrhythmogenic Cardiomyopathy
Official title: Haemodynamics and Ventricular Arrhythmias During Moderate-intensity Endurance and Resistance Exercise in Patients With Arrhythmogenic Cardiomyopathy, a Pilot Study
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Arrhythmias, Cardiac
Lead sponsor: Technical University of Munich
Sponsor class: OTHER
First posted: 2025-02-12
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Intervention model description: In this interventional study patients will be separated into 2 groups with 10 patients per group Group 1: Patients with an implantable cardioverter-defibrillator Group 2: Patients without an implantable cardioverter-defibrillator
Primary purpose: DIAGNOSTIC

Brief summary: Patients with arrhythmogenic cardiomyopathy (ACM) are recommended to refrain from high intensity exercise due to an increased risk of malignant arrhythmias. However, little is known about the effects of prolonged, low-to moderate endurance or resistance exercise on the burden of arrhythmias or central haemodynamics. This pilot interventional study assesses the impact of these modes of exercise on the electrophysiological substrate of the right ventricle (RV), measured by mapping of the RV, and central haemodynamics assessed by right heart catheterization. Patients older than 18 years of age with diagnosed ACM are included with or without implantable cardioverter-defibrillator (ICD).

Detailed description: This is a one-armed, monocentric, unblinded pilot interventional study. Upon fulfilment of the inclusion criteria (age \>18 years of age, diagnosis of ACM with or without implantable cardioverter defibrillator, ICD) and informed consent, patients will have two visits within one week.

The baseline exam (V1), consists of a clinical history, a questionnaire on the quality of life (Kansas City Cardiomyopathy Questionnaire, KCCQ), laboratory examination, echocardiography, 24h-Holter monitoring, and exertional cardiopulmonary exercise testing (CPET). Morphological (echocardiography) and functional (CPET) capacity of the participants will be assessed. With the aid of CPET, exercise intensity for continuous low to moderate-intensity endurance exercise during exercise right heart catheterization (exRHC) will be assessed (heart rate during exRHC will be prescribed at 70% of peak oxygen consumption, VO2peak) and the number of premature ventricular beats (PVB) will be recorded. During V1 the one repetition maximum (1RPM) of isometric handgrip strength will be assessed as well as during dynamic flexion of the upper arm (biceps curl) with the contralateral arm of the planned venous puncture during the invasive testing.

Invasive Testing (V2): V2 will follow 48 hours after V1. Assessment of the number of PVBs will be done at the end of each of the 5 conditions. Patients will first undergo supine resting right heart catheterization (RHC) followed by an electrophysiological study with mapping of the right ventricle (RV mapping) (condition 1, rest). Access for both procedures will be gained via the right internal jugular vein. After a 5-minute break isometric handgrip testing will assess haemodynamic changes (condition 2, isometric resistance test at 70% of the 1RPM for one minute). After another 5-minute break dynamic resistance testing will assess haemodynamic alterations (condition 3, dynamic resistance test, biceps curl at 70% of 1RPM for one minute with the contralateral arm of venous puncture). Following another 5-minute break, patients will perform supine bicycle exercise testing and haemodynamic measurements will be obtained at the end of 20 minutes of continuous, low to moderate-intensity endurance exercise (heart rate at 70% of VO2peak, condition 4, 20 minutes of moderate-intensity endurance test). Following haemodynamic testing, a prolonged low to moderate-intensity endurance exercise test will follow for another 20 minutes (heart rate at 70% of VO2peak), leading to a total time of 40 minutes, which is double the recommended duration from sports cardiology guidelines. Assessment of haemodynamics and RV mapping will be done at the end of this test (condition 5, 40-minutes low to moderate-intensity endurance test).

Following invasive testing, patients without an ICD will receive an implantable loop recorder (ILR).

The aim of this interventional study is to assess the burden of PVBs and changes of voltage maps during each of the exercise modes (20 minutes endurance test vs. 40 minutes endurance test vs. isometric handgrip vs. dynamic resistance exercise) as well as the change of pulmonary pressures. As patients with an ICD represent a high risk category, electrical and haemodynamic properties are compared between groups (ICD yes vs. no) in an exploratory approach. In this interventional study, which consists of assessments which are not part of routine medical care, the haemodynamic and electrophysiological effects of different exercise interventions (endurance and resistance tests) are evaluated.

Eligibility criteria: Inclusion Criteria:

* Age \>18 years of age
* Diagnosis of arrhythmogenic cardiomyopathy (ACM) with or without implantable cardioverter defibrillator (ICD)

Exclusion Criteria:

* Age \<18 years of age
* Intracardiac shunts
* Pre-existing precapillary pulmonary hypertension
* Instable coronary artery disease in clinical assessment
* History of ablation therapy for atrial fibrillation of ventricular tachycardia (VT)
* More than grade I valvular heart disease at resting echocardiography

Primary outcomes:
measure: Difference of the ratio of mean pulmonary artery pressure and cardiac output (mPAP/CO) between rest and the exercise tests in a patient
timeFrame: Through study completion, 48 hours after cardiopulmonary exercise testing (Visit 1)
Secondary outcomes:
measure: Difference of the pulmonary pulsatility index (PAPi) between rest and the exercise tests in a patient
timeFrame: Through study completion, 48 hours after cardiopulmonary exercise testing (Visit 1)
measure: Difference of the ratio of right atrial pressure to pulmonary artery wedge pressure (RA/PAWP) between rest and the exercise tests in a patient
timeFrame: Through study completion, 48 hours after cardiopulmonary exercise testing (Visit 1)
measure: Difference of right ventricular power output reserve (RVPO reserve) between rest and exercise tests in a patient
timeFrame: Through study completion, 48 hours after cardiopulmonary exercise testing (Visit 1)
measure: Total number of premature ventricular beats (PVB) during resting and the different exercise modes per patient
timeFrame: Through study completion, 48 hours after cardiopulmonary exercise testing (Visit 1)
measure: Change in voltage maps during resting and the different exercise modes per patient
timeFrame: Through study completion, 48 hours after cardiopulmonary exercise testing (Visit 1)
measure: Between group differences of the changes in the ratio of mean pulmonary artery pressure and cardiac output (mPAP/CO) between rest and the exercise tests
timeFrame: Through study completion, 48 hours after cardiopulmonary exercise testing (Visit 1)
measure: Between group differences of the number of premature ventricular beats (PVB) between rest and the exercise tests
timeFrame: Through study completion, 48 hours after cardiopulmonary exercise testing (Visit 1)
measure: Between group differences of the changes in voltage maps of the right ventricle between rest and the exercise tests.
timeFrame: Through study completion, 48 hours after cardiopulmonary exercise testing (Visit 1)
Other outcomes:
Locations:
Study officials:
affiliation: Technical University Munich
name: Simon Wernhart, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Wernhart S, Goertz A, Hedderich J, Papathanasiou M, Hoffmann J, Rassaf T, Luedike P. Diastolic exercise stress testing in heart failure with preserved ejection fraction: The DEST-HF study. Eur J Heart Fail. 2023 Oct;25(10):1768-1780. doi: 10.1002/ejhf.2995. Epub 2023 Aug 24.
citation: Gasperetti A, Rossi VA, Chiodini A, Casella M, Costa S, Akdis D, Buchel R, Deliniere A, Pruvot E, Gruner C, Carbucicchio C, Manka R, Dello Russo A, Tondo C, Brunckhorst C, Tanner F, Duru F, Saguner AM. Differentiating hereditary arrhythmogenic right ventricular cardiomyopathy from cardiac sarcoidosis fulfilling 2010 ARVC Task Force Criteria. Heart Rhythm. 2021 Feb;18(2):231-238. doi: 10.1016/j.hrthm.2020.09.015. Epub 2020 Sep 22.
citation: Sawant AC, Te Riele AS, Tichnell C, Murray B, Bhonsale A, Tandri H, Judge DP, Calkins H, James CA. Safety of American Heart Association-recommended minimum exercise for desmosomal mutation carriers. Heart Rhythm. 2016 Jan;13(1):199-207. doi: 10.1016/j.hrthm.2015.08.035. Epub 2015 Aug 29.
citation: Marcus FI, McKenna WJ, Sherrill D, Basso C, Bauce B, Bluemke DA, Calkins H, Corrado D, Cox MG, Daubert JP, Fontaine G, Gear K, Hauer R, Nava A, Picard MH, Protonotarios N, Saffitz JE, Sanborn DM, Steinberg JS, Tandri H, Thiene G, Towbin JA, Tsatsopoulou A, Wichter T, Zareba W. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the Task Force Criteria. Eur Heart J. 2010 Apr;31(7):806-14. doi: 10.1093/eurheartj/ehq025. Epub 2010 Feb 19.
citation: Corrado D, Anastasakis A, Basso C, Bauce B, Blomstrom-Lundqvist C, Bucciarelli-Ducci C, Cipriani A, De Asmundis C, Gandjbakhch E, Jimenez-Jaimez J, Kharlap M, McKenna WJ, Monserrat L, Moon J, Pantazis A, Pelliccia A, Perazzolo Marra M, Pillichou K, Schulz-Menger J, Jurcut R, Seferovic P, Sharma S, Tfelt-Hansen J, Thiene G, Wichter T, Wilde A, Zorzi A. Proposed diagnostic criteria for arrhythmogenic cardiomyopathy: European Task Force consensus report. Int J Cardiol. 2024 Jan 15;395:131447. doi: 10.1016/j.ijcard.2023.131447. Epub 2023 Oct 14.
citation: Cadrin-Tourigny J, Bosman LP, James CA. Sudden cardiac death risk prediction in arrhythmogenic right ventricular cardiomyopathy: a practical approach to navigating the challenges of prediction models. Eur Heart J. 2022 Dec 14;43(47):4961-4962. doi: 10.1093/eurheartj/ehac562. No abstract available.
citation: Corrado D, Wichter T, Link MS, Hauer R, Marchlinski F, Anastasakis A, Bauce B, Basso C, Brunckhorst C, Tsatsopoulou A, Tandri H, Paul M, Schmied C, Pelliccia A, Duru F, Protonotarios N, Estes NA 3rd, McKenna WJ, Thiene G, Marcus FI, Calkins H. Treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia: an international task force consensus statement. Eur Heart J. 2015 Dec 7;36(46):3227-37. doi: 10.1093/eurheartj/ehv162. Epub 2015 Jul 27. No abstract available.
citation: Saberniak J, Hasselberg NE, Borgquist R, Platonov PG, Sarvari SI, Smith HJ, Ribe M, Holst AG, Edvardsen T, Haugaa KH. Vigorous physical activity impairs myocardial function in patients with arrhythmogenic right ventricular cardiomyopathy and in mutation positive family members. Eur J Heart Fail. 2014 Dec;16(12):1337-44. doi: 10.1002/ejhf.181. Epub 2014 Oct 16.